Cardiovascular-focused Kardigan Inc. is the latest biopharma firm to take advantage of the wide open IPO window, pricing an upsized offering of 25 million shares at $16 per share, the high end of its proposed range, to rake in gross proceeds of about $400 million.
Chinese peptide therapeutics developer Shaanxi Micot Pharmaceutical Technology Co. Ltd. is seeking up to HK$1.22 billion (US$155 million) in a Hong Kong IPO to advance its lead phase III chronic kidney disease candidate, MT-1013, and next-generation obesity therapies.
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead programs.
Biopharma and med-tech companies raising money in public or private financings, including: Arcadia, Adial, Azora, Enliven, Human Continuum, Parabilis, Regeneron.
Biopharma and med-tech companies raising money in public or private financings, including: Atossa, Cequr, Edesa, Humacyte, Ideaya, Kardigan, Nyxoah, Thruflo.
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone receptor, at the Endocrine Society’s 2026 annual meeting on June 15.
Biopharma and med-tech companies raising money in public or private financings, including: Aim Immunotech, Antogen, Cerus, City, Corvus, Dicot, Eloxx, Ideaya, Idorsia, Shattuck, Starton.
RSS
